Skip to main content

Table 1 (abstract P22). Effect of erenumab in patients achieving ≥50% response in MMDs vs non-responders and overall population

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Outcome measures Erenumab 70 mg Erenumab 140 mg
≥50% Responders
(N=75)
Non-responders
(N=113)
Overall population
(N=188)
≥50% Responders
(N = 77)
Non-responders
(N =110)
Overall population
(N=187)
Change from baseline to Week 12
 MMD −12.2 (2.9) −2.6 (4.3) −6.6 (6.1) −12.5 (4.6) −2.2 (4.4) −6.5 (6.8)
 MSMD −5.2 (5.2) −1.8 (4.1) −3.3 (4.9) −6.9 (5.6) −2.4 (3.9) −4.3 (5.2)
 HIT-6 −10.0 (7.6) −2.8 (5.1) −5.7 (7.2) −10.7 (8.0) −1.7 (5.1) −5.5 (7.9)
 MIDAS total score −29.1 (45.4) −12.6 (41.5) −19.5 (43.8) −35.0 (45.2) −5.8 (38.4) −18.1 (43.7)
 MSQ-RFP 23.0 (19.4) 6.0 (19.8) 13.0 (21.3) 25.7 (23.2) 4.8 (16.2) 13.7 (22.1)
 MSQ-RFR 29.7 (18.6) 9.4 (19.8) 17.7 (21.7) 32.7 (23.7) 8.2 (18.5) 18.7 (24.1)
 MSQ-EF 30.5 (25.4) 11.1 (26.7) 19.1 (27.8) 33.3 (27.2) 6.3 (19.9) 17.8 (26.8)
  1. Data are expressed as mean (SD)
  2. HIT-6 Headache Impact Test (higher score indicates worse outcome), MIDAS Migraine Disability Assessment (higher score indicates worse outcomes), MMD monthly migraine days, MSQ Migraine-Specific Quality-of-Life Questionnaire (higher scores indicate better outcomes), MSQ-RFR Migraine-Specific Quality-of-Life Questionnaire role function-restrictive, MSQ-RFP Migraine-Specific Quality-of-Life Questionnaire role function-preventive, MSQ-EF Migraine-Specific Quality-of-Life Questionnaire emotional functioning, SD standard deviation